The discovery that certain high-risk strains of human papillomavirus (HR-HPV) cause nearly 100% of invasive cervical cancer has spurred a revolution in cervical cancer prevention by promoting the development of viral vaccines. Although the efficacy of these vaccines has already been demonstrated, a complete understanding of viral latency and natural immunity is lacking, and solving these mysteries could help guide policies of cervical cancer screening and vaccine use. Here, we examine the epidemiological and biological understanding of the natural history of HPV infection, with an eye toward using these studies to guide the implementation of cervical cancer prevention strategies.
Patti E. Gravitt
Title and authors | Publication | Year |
---|---|---|
Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas
L Yu, X Tian, C Gao, P Wu, L Wang, B Feng, X Li, H Wang, D Ma, Z Hu |
Frontiers of Medicine | 2018 |
Redetection of human papillomavirus type 16 infections of the cervix in mid-adult life
A Ermel, ML Shew, TM Imburgia, M Brown, B Qadadri, Y Tong, DR Brown |
Papillomavirus Research | 2018 |
Genetic variant in CXCL12 gene raises susceptibility to HPV infection and squamous intraepithelial lesions development: a case-control study
NC Okuyama, F Cezar-dos-Santos, ÉR Pereira, KP Trugilo, GC Cebinelli, MM Sena, AP Pereira, AM Aranome, LF Mangieri, RS Ferreira, MA Watanabe, KB de Oliveira |
Journal of Biomedical Science | 2018 |